Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Eloralintide

Stage Phase 3Stale

Sponsor Eli Lilly and Company

Route subcutaneous

Class Amylin

Mechanism selective amylin receptor agonist

Target amylin receptor (TEC-0022)

Sources

publication, as of 2025-11-06Stale

https://pubmed.ncbi.nlm.nih.gov/41207310/

Eloralintide is a novel, selective amylin receptor agonist. Participants received once-per-week subcutaneous injections. The mean percent change in bodyweight from baseline after 48 weeks (efficacy estimand) was -9% (1 mg), -12% (3 mg), -18% (6 mg), and -20% (9 mg), compared with -0.4% in the placebo group.

Lancet 2025;406:2631-2643, PMID 41207310, NCT06230523, abstract

registry, as of 2026-06-24Stale

https://clinicaltrials.gov/study/NCT06230523

Protocol section, NCT06230523, last update posted 2026-06-24

registry, as of 2026-09-22Stale

https://clinicaltrials.gov/study/NCT07321886

Protocol section, NCT07321886 ENLIGHTEN-1, last update posted 2026-09-22

registry, as of 2026-11-03

https://clinicaltrials.gov/study/NCT07900633

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 3000. Conditions Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2. The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.

ClinicalTrials.gov NCT07900633 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1035. Conditions Overweight; Obesity. The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

ClinicalTrials.gov NCT07282600 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 900. Conditions Overweight; Obesity. The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last abo

ClinicalTrials.gov NCT07392190 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07353931

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 900. Conditions Osteoarthritis; Overweight or Obesity. The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the

ClinicalTrials.gov NCT07353931 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07369011

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Sleep Apnea, Obstructive; Obesity; Overweight. The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will inclu

ClinicalTrials.gov NCT07369011 protocol and results modules

registry, as of 2026-10-08Stale

https://clinicaltrials.gov/study/NCT07589608

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 400. Conditions Overweight; Obesity. The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes.

ClinicalTrials.gov NCT07589608 protocol and results modules

registry, as of 2026-10-09Stale

https://clinicaltrials.gov/study/NCT07215559

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 200. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

ClinicalTrials.gov NCT07215559 protocol and results modules

registry, as of 2026-07-16Stale

https://clinicaltrials.gov/study/NCT07665879

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 115. Conditions Overweight; Obesity. The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each p

ClinicalTrials.gov NCT07665879 protocol and results modules

registry, as of 2026-08-14Stale

https://clinicaltrials.gov/study/NCT07765511

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 60. Conditions Obesity; Overweight. The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate ho

ClinicalTrials.gov NCT07765511 protocol and results modules

registry, as of 2026-08-20Stale

https://clinicaltrials.gov/study/NCT07738614

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 56. Conditions Obesity; Overweight. The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU)

ClinicalTrials.gov NCT07738614 protocol and results modules

registry, as of 2026-10-08Stale

https://clinicaltrials.gov/study/NCT07808060

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 34. Conditions Obesity; Overweight. The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Re

ClinicalTrials.gov NCT07808060 protocol and results modules

registry, as of 2025-11-19Stale

https://clinicaltrials.gov/study/NCT06916091

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 30. Conditions Obesity; Overweight. The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check h

ClinicalTrials.gov NCT06916091 protocol and results modules

Studies

NCT06230523

Registry NCT06230523

Phase Phase 2

Status Completed

Enrollment 263

Start 2024-02-05

Primary completion 2025-05-30

Study completion 2025-08-14

Placebo

Regimen once weekly

Weeks 48

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

percent change in bodyweight, -0.4 %, week 48Stale

1 mg Eloralintide

Dose 1 mg

Regimen once weekly

Weeks 48

Comparator placebo

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

percent change in bodyweight, -9 %, week 48Stale

3 mg Eloralintide

Dose 3 mg

Regimen once weekly

Weeks 48

Comparator placebo

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

percent change in bodyweight, -12 %, week 48Stale

6 mg Eloralintide

Dose 6 mg

Regimen once weekly

Weeks 48

Comparator placebo

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

percent change in bodyweight, -18 %, week 48Stale

9 mg Eloralintide

Dose 9 mg

Regimen once weekly

Weeks 48

Comparator placebo

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

percent change in bodyweight, -20 %, week 48Stale

6/9 mg Eloralintide

Dose 6/9 mg

Regimen once weekly

Weeks 48

Comparator placebo

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

3/6/9 mg Eloralintide

Dose 3/6/9 mg

Regimen once weekly

Weeks 48

Comparator placebo

Population adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes

Estimand Efficacy

ENLIGHTEN-1

Registry NCT07321886

Phase Phase 3

Status Recruiting

Enrollment 1980

Start 2026-02-06

Catalyst Primary completion. 2028-03-01Stale

Eloralintide Dose 1

Eloralintide Dose 2

Eloralintide Dose 3

Eloralintide Dose 4

Placebo

ENLIGHTEN-10

Registry NCT07900633

Phase Phase 3

Status Not yet recruiting

Enrollment 3000

Eloralintide

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2

Placebo

Regimen once weekly

Population Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2

ENLIGHTEN-2

Registry NCT07282600

Phase Phase 3

Status Recruiting

Enrollment 1035

Start 2025-12-15

Eloralintide Dose 1

Regimen once weekly

Weeks 75

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 2

Regimen once weekly

Weeks 75

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 3

Regimen once weekly

Weeks 75

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 4

Regimen once weekly

Weeks 75

Comparator placebo

Population Overweight; Obesity

Placebo

Regimen once weekly

Weeks 75

Population Overweight; Obesity

ENLIGHTEN-6

Registry NCT07392190

Phase Phase 3

Status Recruiting

Enrollment 900

Start 2026-02-10

Eloralintide Dose 1

Regimen once weekly

Weeks 80

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 2

Regimen once weekly

Weeks 80

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 3

Regimen once weekly

Weeks 80

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 4

Regimen once weekly

Weeks 80

Comparator placebo

Population Overweight; Obesity

Placebo

Regimen once weekly

Weeks 80

Population Overweight; Obesity

ENLIGHTEN-4

Registry NCT07353931

Phase Phase 3

Status Recruiting

Enrollment 900

Start 2026-02-09

Eloralintide (YOA1)

Regimen once weekly

Weeks 75

Comparator placebo

Population Osteoarthritis; Overweight or Obesity

Placebo (YOA1)

Regimen once weekly

Weeks 75

Population Osteoarthritis; Overweight or Obesity

Eloralintide (YOA2)

Regimen once weekly

Weeks 75

Comparator placebo

Population Osteoarthritis; Overweight or Obesity

Placebo (YOA2)

Regimen once weekly

Weeks 75

Population Osteoarthritis; Overweight or Obesity

ENLIGHTEN-3

Registry NCT07369011

Phase Phase 3

Status Recruiting

Enrollment 800

Start 2026-02-10

Eloralintide (YSA1)

Regimen once weekly

Weeks 76

Comparator placebo

Population Sleep Apnea, Obstructive; Obesity; Overweight

Placebo (YSA1)

Regimen once weekly

Weeks 76

Population Sleep Apnea, Obstructive; Obesity; Overweight

Eloralintide (YSA2)

Regimen once weekly

Weeks 76

Comparator placebo

Population Sleep Apnea, Obstructive; Obesity; Overweight

Placebo (YSA2)

Regimen once weekly

Weeks 76

Population Sleep Apnea, Obstructive; Obesity; Overweight

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Registry NCT07589608

Phase Phase 2

Status Recruiting

Enrollment 400

Start 2026-05-15

Macupatide Dose 1

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 1

Comparator placebo

Population Overweight; Obesity

Macupatide Dose 1 + Eloralintide Dose 1

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 2

Comparator placebo

Population Overweight; Obesity

Macupatide Dose 1 + Eloralintide Dose 2

Comparator placebo

Population Overweight; Obesity

Eloralintide Dose 3

Comparator placebo

Population Overweight; Obesity

Macupatide Dose 2 + Eloralintide Dose 3

Comparator placebo

Population Overweight; Obesity

Placebo

Population Overweight; Obesity

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Registry NCT07215559

Phase Phase 2

Status Active, not recruiting

Enrollment 200

Start 2025-10-16

Macupatide (Macupatide + Eloralintide Placebo)

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Eloralintide (Elorlintide + Macupatide Placebo)

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Macupatide + Eloralintide

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Placebo (Macupatide Placebo + Elorlintide Placebo)

Population Obesity; Overweight; Diabetes Mellitus, Type 2

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Registry NCT07665879

Phase Phase 1

Status Recruiting

Enrollment 115

Start 2026-06-24

Eloralintide

Comparator placebo

Population Overweight; Obesity

Placebo

Population Overweight; Obesity

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Registry NCT07765511

Phase Phase 1

Status Not yet recruiting

Enrollment 60

Macupatide + placebo

Population Obesity; Overweight

Eloralintide + placebo

Population Obesity; Overweight

Macupatide Dose A + Eloralintide

Comparator placebo

Population Obesity; Overweight

Macupatide Dose B + Eloralintide

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Registry NCT07738614

Phase Phase 1

Status Recruiting

Enrollment 56

Start 2026-07-31

Eloralintide Cohort 1

Comparator placebo

Population Obesity; Overweight

Eloralintide Cohort 2

Comparator placebo

Population Obesity; Overweight

Eloralintide Cohort 3

Comparator placebo

Population Obesity; Overweight

Eloralintide Cohort 4

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

Registry NCT07808060

Phase Phase 1

Status Recruiting

Enrollment 34

Start 2026-09-15

Eloralintide and combined oral contraceptive

Population Obesity; Overweight

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Registry NCT06916091

Phase Phase 1

Status Completed

Enrollment 30

Start 2025-04-21

Primary completion 2025-09-09

Study completion 2025-09-09

Catalyst Primary completion. 2025-09-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Eloralintide

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight